help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moattari, A. R.
Right arrow Articles by Vinik, A. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moattari, A. R.
Right arrow Articles by Vinik, A. I.

Journal of Clinical Endocrinology & Metabolism, Vol 69, 902-905, Copyright © 1989 by Endocrine Society

ARTICLES

Effects of sandostatin on plasma chromogranin-A levels in neuroendocrine tumors

AR Moattari, LJ Deftos and AI Vinik
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109.

We have determined the effects of Sandostatin (SMS 201-995, Sandoz) on chromogranin-A (CgA) in the blood of 14 patients with neuroendocrine tumors of the gastroenteropancreatic axis, 7 with carcinoid tumors, 5 with gastrinomas, and 1 each with a glucagonoma and tumor-secreting vasoactive intestinal peptide. Two thirds of the patients had elevated plasma CgA. Sandostatin administration suppressed CgA in 12 of the 14 patients. In 8 of 10, the clinical response to Sandostatin paralleled the reduction in CgA levels. There was a strong correlation between the change in CgA levels and the respective blood concentration of the hormone produced by the tumor. Serial measurement of CgA may provide an additional means of monitoring these tumors and their secretory activity where other measures are not available.


This article has been cited by other articles:


Home page
 JCOHome page
D. Campana, F. Nori, L. Piscitelli, A. M. Morselli-Labate, R. Pezzilli, R. Corinaldesi, and P. Tomassetti
Chromogranin A: Is It a Useful Marker of Neuroendocrine Tumors?
J. Clin. Oncol., May 20, 2007; 25(15): 1967 - 1973.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1989 by The Endocrine Society